Development of Radiomic-Based Model to Predict Clinical Outcomes in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy

SIMPLE SUMMARY: In locally advanced or metastatic non-small cell lung cancer (NSCLC), immunotherapy has become a standard as it can improve overall survival and progression-free survival. However, a durable clinical benefit (DCB) is only achieved in 20–50% of patients. Early identification of patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Tankyevych, Olena, Trousset, Flora, Latappy, Claire, Berraho, Moran, Dutilh, Julien, Tasu, Jean Pierre, Lamour, Corinne, Cheze Le Rest, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739232/
https://www.ncbi.nlm.nih.gov/pubmed/36497415
http://dx.doi.org/10.3390/cancers14235931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739232/
https://www.ncbi.nlm.nih.gov/pubmed/36497415
http://dx.doi.org/10.3390/cancers14235931

Ejemplares similares